Skip to main content

Accelerating Medicines Partnership Alzheimer’s Disease (AMP AD 1.0)

The Accelerating Medicines Partnership Alzheimer's Disease (AMP AD) is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease. The first iteration of the AMP AD public-private partnership (AMP AD 1.0) was focused on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. AMP AD 1.0 was launched in 2014 and was implemented through two projects: the Biomarkers in Clinical Trials Project and the Target Discovery and Preclinical Validation Project.

AMP AD Biomarkers in Clinical Trials Project

The AMP AD Biomarkers Project is comprised of two NIA-supported Phase II/III secondary prevention trials testing several anti-amyloid therapies. The goal is to explore the utility of tau imaging for tracking responsiveness to treatment and/or disease progression.

Biomarkers in Clinical Trials Project Grants

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Trial (A4 Trial) (U19AG010483)
Principal Investigators:
Reisa Sperling, Brigham and Women’s Hospital and Harvard Medical School
Paul Aisen, University of Southern California

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study (R01AG063689)
Principal Investigators:
Reisa Sperling, Brigham and Women's Hospital and Harvard Medical School
Paul Aisen, University of Southern California

Dominantly Inherited Alzheimer Network (DIAN) Trial (U01AG042791)
Principal Investigator:
Randall Bateman, Washington University

Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) (R01AG046179)
Principal Investigator:
Randall Bateman, Washington University

AMP AD Target Discovery and Preclinical Validation Project

The central goal of the AMP AD Target Discovery and Preclinical Validation Project was to shorten the time between the discovery of potential drug targets and the development of new drugs for Alzheimer’s disease treatment and prevention, by integrating the analyses of large-scale molecular data from human brain samples with network modeling approaches and experimental validation.

The project was a consortium of six multi-institutional, multidisciplinary cooperative agreement grants. The grant awardees applied cutting-edge systems and network biology approaches to integrate multidimensional human “omic” data (genomic, epigenomic, RNAseq, proteomic) from more than 2,000 human brains at all stages of the disease with clinical and pathological data to:

  • Discover novel therapeutic targets for Alzheimer’s disease
  • Gain a systems-level understanding of the gene, protein, and metabolic networks within which these novel targets operate
  • Evaluate their druggability in multiple model organisms

To achieve this project’s central goal, grant awardees were expected to engage in broad sharing of biological data, analytical methodology, and disease models before publication. Rapid sharing of data and analytical tools was enabled through the centralized data infrastructure, the AD Knowledge Portal and Agora, two resources developed by the AMP AD Data Coordinating Center at Sage Bionetworks under the leadership of Lara Mangravite.

More information about the AMP AD Data Infrastructure.

Target Discovery and Preclinical Validation Grants

Pathway Discovery, Validation and Compound Identification for Alzheimer’s Disease (U01AG046152)
Contact Principal Investigator:
Philip L. De Jager, Brigham and Women’s Hospital and the Broad Institute, Inc.

Integrative Biology Approach to Complexity of Alzheimer’s Disease (U01AG046170)
Contact Principal Investigator:
Eric E. Schadt, Icahn School of Medicine at Mount Sinai

A System Approach to Targeting Innate Immunity in Alzheimer’s Disease (U01AG046139)
Contact Principal Investigator:
Todd E. Golde, University of Florida

Discovery of Novel Proteomic Targets for Treatment of Alzheimer’s Disease (U01AG046161)
Contact Principal Investigator:
Allan I. Levey, Emory University

Metabolic Networks and Pathways in Alzheimer’s Disease (R01AG046171)
Principal Investigator:
Rima F. Kaddurah-Daouk, Duke University

Targeting a Novel Regulator of Brain Aging and Alzheimer’s Disease (R01AG046174)
Contact Principal Investigator:
Bruce Yankner, Harvard University

In 2017, the NIA enhanced the research-scope of the Target Discovery and Preclinical Validation Project by supporting five additional research grants (AMP AD enhancer grants) through the funding initiative Enhancing the Target and Biomarker Discovery Efforts of the AMP AD and M20VE-AD Consortia (RFA-AG-17-054). Collectively these grants enhanced the AMP AD data infrastructure and analytical capabilities and led to the generation of new human multi-omic data from brain, CSF, and blood samples, as well as single nucleus profiling data (human and mouse brain).

Open Systems for AMP AD Target Enhancement (RF1AG057443)
Contact Principal Investigator:
Lara Mangravite, Sage Bionetworks

Building Novel Predictive Networks for High-Throughput, in-Silico Key Driver Prioritization to Enhance Drug Target Discovery in AMP AD and M2OVE-AD (RF1AG057457)
Contact Principal Investigator:
Rui Chang, University of Arizona

Deconstructing and Modeling the Single Cell Architecture of the Alzheimer Brain (RF1AG057473)
Contact Principal Investigator:
Philip L. De Jager, Columbia University Health Sciences

Towards a Comprehensive Signaling Pathway Map of Parahippocampal Vulnerability in Alzheimer’s Disease (RF1AG057440)
Contact Principal Investigator:
Bin Zhang, Icahn School of Medicine at Mount Sinai

Metabolic Network Analysis of Biochemical Trajectories in Alzheimer’s Disease (RF1AG057452)
Contact Principal Investigator:
Rima F. Kaddurah-Daouk, Duke University

Brain-Plasma Proteomics Biomarker Discovery and Validation in the US and UK (RF1AG057471)
Contact Principal Investigator:
Allan I. Levey, Emory University

AMP AD 1.0 Funding

Funding: 5 years (2014-2018)*
Total project** funding ($M) Total NIH funding ($M) Total industry** funding ($M) Total nonprofit funding ($M)
$185.2* $162 $22.2 $1.0
  • *Does not include AMP AD enhancer grants.
  • **Does not include in-kind contributions of $40M.

AMP AD 1.0 Partners and Governance

Partner organizations

Government

Industry

Nonprofit

Governance

AMP is a multi-sector partnership managed by the Foundation for the NIH (FNIH). NIH and industry partners share expertise and resources in an integrated governance structure that enables the best-informed contributions to science from all participants.

Each AMP disease area has a steering committee comprising representatives from the administering NIH Institute, the FDA, industry, and nonprofit foundations. The disease-specific steering committees are managed by the FNIH under the direction of the AMP Executive Committee, which includes leaders from NIH, FDA, participating industry partners, and patient advocacy organizations.

The AMP AD Steering Committee convenes monthly to discuss project plans and review ongoing progress and milestones. NIA program staff members provide scientific and administrative direction and oversees the cooperative grants that constitute the Target Discovery and the Biomarkers AMP AD consortia. The AMP AD program has several working groups that bring together scientists from the academic and industry teams. Face-to-face meetings organized by NIA with support from the FNIH provide an additional venue for communication and coordination.

View Other AMP AD Pages